Canada Pension Plan Investment Board Has $433.06 Million Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Canada Pension Plan Investment Board raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.5% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 973,492 shares of the medical equipment provider’s stock after purchasing an additional 165,712 shares during the period. Canada Pension Plan Investment Board’s holdings in Intuitive Surgical were worth $433,058,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ISRG. Gilbert & Cook Inc. grew its holdings in Intuitive Surgical by 6.5% in the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after buying an additional 211 shares in the last quarter. TrinityPoint Wealth LLC grew its holdings in Intuitive Surgical by 21.5% in the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after buying an additional 191 shares in the last quarter. Sachetta LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth $32,000. D.A. Davidson & CO. grew its holdings in shares of Intuitive Surgical by 4.1% during the 4th quarter. D.A. Davidson & CO. now owns 12,726 shares of the medical equipment provider’s stock worth $4,293,000 after purchasing an additional 506 shares in the last quarter. Finally, CreativeOne Wealth LLC grew its holdings in shares of Intuitive Surgical by 4.8% during the 4th quarter. CreativeOne Wealth LLC now owns 1,646 shares of the medical equipment provider’s stock worth $555,000 after purchasing an additional 75 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ISRG. Redburn Atlantic raised Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their target price for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Robert W. Baird increased their target price on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a report on Friday, July 19th. Stifel Nicolaus increased their target price on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Morgan Stanley upped their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Finally, JPMorgan Chase & Co. upped their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $490.01 on Friday. The business has a 50 day simple moving average of $467.17 and a 200 day simple moving average of $424.26. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $496.18. The stock has a market capitalization of $173.81 billion, a P/E ratio of 88.45, a P/E/G ratio of 5.41 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter last year, the firm posted $1.18 earnings per share. The firm’s revenue was up 14.5% on a year-over-year basis. Equities analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock valued at $25,528,753 over the last 90 days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.